Drug class
"Antineoplastic Antibody/Radioactive-Drug Complexes" is a specific formulary classification term (such as in First Databank's HIC3 classification system, code V1U) used for radiolabeled monoclonal antibodies, clinically referred to as radioimmunotherapeutics or antibody-radionuclide conjugates. Read more about Antineoplastic Antibody/Radioactive-Drug Complexes
2 drugs in this class 1 manufacturers
"Antineoplastic Antibody/Radioactive-Drug Complexes" is a specific formulary classification term (such as in First Databank's HIC3 classification system, code V1U) used for radiolabeled monoclonal antibodies, clinically referred to as radioimmunotherapeutics or antibody-radionuclide conjugates.
Rather than an official FDA regulatory designation, this classification describes targeted biologics in which a monoclonal antibody is conjugated to a radioactive isotope.
The antibody selectively binds to tumor-specific cell surface antigens, delivering cytotoxic ionizing radiation directly to cancer cells and adjacent tumor tissue to induce DNA damage and cell death.
Historically, this therapeutic approach has primarily been approved and utilized in hematologic oncology, particularly CD20-targeted regimens for non-Hodgkin lymphoma.
"Antineoplastic Antibody/Radioactive-Drug Complexes" is a specific formulary classification term (such as in First Databank's HIC3 classification system, code V1U) used for radiolabeled monoclonal antibodies, clinically referred to as radioimmunotherapeutics or antibody-radionuclide conjugates
"Antineoplastic Antibody/Radioactive-Drug Complexes" is a specific formulary classification term (such as in First Databank's HIC3 classification system, code V1U) used for radiolabeled monoclonal antibodies, clinically referred to as radioimmunotherapeutics or antibody-radionuclide conjugates
Rather than an official FDA regulatory designation, this classification describes targeted biologics in which a monoclonal antibody is conjugated to a radioactive isotope
Rather than an official FDA regulatory designation, this classification describes targeted biologics in which a monoclonal antibody is conjugated to a radioactive isotope
The antibody selectively binds to tumor-specific cell surface antigens, delivering cytotoxic ionizing radiation directly to cancer cells and adjacent tumor tissue to induce DNA damage and cell death
Historically, this therapeutic approach has primarily been approved and utilized in hematologic oncology, particularly CD20-targeted regimens for non-Hodgkin lymphoma
Historically, this therapeutic approach has primarily been approved and utilized in hematologic oncology, particularly CD20-targeted regimens for non-Hodgkin lymphoma
Following a drug class requires a free Physicians Office Resource account.
